English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, May 11, 2021
Eisai's Statement of Commitment for Carbon Neutrality by 2040
Friday, May 7, 2021
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
エーザイ、「レンビマ」と「キイトルーダ」の併用療法について進行性腎細胞がんおよび進行性子宮内膜がんに係る申請が米国FDAより優先審査に指定
Wednesday, April 28, 2021
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
埼玉りそな銀行とエーザイ、埼玉県における認知症との共生と予防に向け業務提携を締結
Friday, April 23, 2021
エーザイ、「レンビマ(R)」と「キイトルーダ(R)」の併用療法について、日本において進行性子宮体がんに係る適応追加を申請
Monday, December 18, 2017
エーザイ、小中高校生を対象とした、認知症を知り自分にできることを考えるための教材を販売開始
Friday, April 23, 2021
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
エーザイ、アデュカヌマブのブラジル・カナダ・オーストラリア・スイスにおける販売承認申請の提出について

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575